CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy

E-ISSN： 1875-533x|16|15|1831-1849

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.16, Iss.15, 2009-05, pp. : 1831-1849

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents

Drug Design Reviews - Online, Vol. 1, Iss. 2, 2004-04 ,pp. : 123-132

Bentham Science Publishers

Access to resources Recommend Favorite

CDC25 Phosphatase Inhibitors: An Update

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 1, 2012-01 ,pp. : 62-73

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review

By Lavecchia Antonio Di Giovanni Carmen Novellino Ettore

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 3, 2010-03 ,pp. : 405-425

Informa Healthcare

Access to resources Recommend Favorite

The potential of proteasome inhibitors in cancer therapy

By Sterz Jan Metzler Ivana von Hahne Jens-Claus Lamottke Britta Rademacher Jessica Heider Ulrike Terpos Evangelos Sezer Orhan

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 879-895

Informa Healthcare

Access to resources Recommend Favorite

Cathepsin B inhibitors as potential anti-metastatic agents

By Michaud S. Gour B.J.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 6, 1998-06 ,pp. : 645-672

Informa Healthcare

Access to resources Recommend Favorite